advertisement
Eye 22
Showing records 1 to 22 | Display all abstracts in Eye66513 Leading causes of certifiable visual loss in England and Wales during the year ending 31 March 2013
Quartilho A
Eye 2016; 30: 602-607
66602 Visual outcomes and ocular morbidity of patients with uveitis referred to a tertiary center during first year of follow-up
Groen F
Eye 2016; 30: 473-480
66340 Long-term outcomes of neovascular glaucoma treated with and without intravitreal bevacizumab
Olmos LC
Eye 2016; 30: 463-472
65881 A view on glaucoma-are we seeing it clearly?
Crabb DP
Eye 2016; 30: 304-313
65930 Diurnal intraocular pressure fluctuation and its risk factors in angle-closure and open-angle glaucoma
Srinivasan S; Choudhari NS
Eye 2016; 30: 362-368
66340 Long-term outcomes of neovascular glaucoma treated with and without intravitreal bevacizumab
Sayed MS
Eye 2016; 30: 463-472
66602 Visual outcomes and ocular morbidity of patients with uveitis referred to a tertiary center during first year of follow-up
Ramdas W
Eye 2016; 30: 473-480
66513 Leading causes of certifiable visual loss in England and Wales during the year ending 31 March 2013
Simkiss P
Eye 2016; 30: 602-607
65930 Diurnal intraocular pressure fluctuation and its risk factors in angle-closure and open-angle glaucoma
Baskaran M
Eye 2016; 30: 362-368
66340 Long-term outcomes of neovascular glaucoma treated with and without intravitreal bevacizumab
Moraczewski AL
Eye 2016; 30: 463-472
66513 Leading causes of certifiable visual loss in England and Wales during the year ending 31 March 2013
Zekite A
Eye 2016; 30: 602-607
66602 Visual outcomes and ocular morbidity of patients with uveitis referred to a tertiary center during first year of follow-up
de Hoog J
Eye 2016; 30: 473-480
66513 Leading causes of certifiable visual loss in England and Wales during the year ending 31 March 2013
Xing W
Eye 2016; 30: 602-607
66340 Long-term outcomes of neovascular glaucoma treated with and without intravitreal bevacizumab
Gedde SJ
Eye 2016; 30: 463-472
65930 Diurnal intraocular pressure fluctuation and its risk factors in angle-closure and open-angle glaucoma
George RJ
Eye 2016; 30: 362-368
66602 Visual outcomes and ocular morbidity of patients with uveitis referred to a tertiary center during first year of follow-up
Vingerling JR; Rothova A
Eye 2016; 30: 473-480
65930 Diurnal intraocular pressure fluctuation and its risk factors in angle-closure and open-angle glaucoma
Shantha B
Eye 2016; 30: 362-368
66513 Leading causes of certifiable visual loss in England and Wales during the year ending 31 March 2013
Wormald R
Eye 2016; 30: 602-607
66340 Long-term outcomes of neovascular glaucoma treated with and without intravitreal bevacizumab
Rosenfeld PJ
Eye 2016; 30: 463-472
66513 Leading causes of certifiable visual loss in England and Wales during the year ending 31 March 2013
Bunce C
Eye 2016; 30: 602-607
65930 Diurnal intraocular pressure fluctuation and its risk factors in angle-closure and open-angle glaucoma
Vijaya L
Eye 2016; 30: 362-368
66340 Long-term outcomes of neovascular glaucoma treated with and without intravitreal bevacizumab
Shi W; Feuer WJ; Lee RK
Eye 2016; 30: 463-472
